Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.

Abstract: An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.

Abstract: A programmable switching device that employs a Hall Effect sensor and a moving magnet is disclosed. The Hall Effect sensor is electrically connected to a programmable microprocessor that is programmed to detect changes in Hall Effect voltages at the sensor. The programmable switching device may also be configured as a rotary switching device. By using a plurality of magnets and Hall Effect transducers and orienting some magnets with their polarities in different directions, a temper-proof switch can be achieved. The programmable switching device may be connected to a serial bus that is interfaced with an elevator controller.

Abstract: The invention relates to a fixture for insertion into and permanent anchorage in a cavity (32) formed in bone tissue. The fixture is made of a fixture member (2), which has an insertion end surface (10) and a cylindrical peripheral surface (6) provided with screw threads, and a plurality of circumferentially-spaced cutting recesses (9), which are formed in a forward, self-tapping end portion (7) of the threaded peripheral surface (6) adjacent to the insertion end surface (10) and which open axially into the insertion end surface (10). A plurality of circumferentially-spaced tissue-collecting and tissue-distributing grooves (17) are formed in a rear, non-self-tapping portion (8) of the threaded peripheral surface (6).

Abstract: An enteric coated pharmaceutical dosage form comprising an H+,K+-ATPase inhibitor is disclosed. The dosage form comprises at least two portions of the H+,K+- ATPase inhibitor to be released in at least two consecutive pulses. The dosage form has at least one fraction with a pulsed delayed release and another fraction with instant release of the H+,K+-ATPase inhibitor. The portions are released in time by from 0.5 and up to 12 hours interval, preferably by from 0.5 and up to 8 hours, and more preferably by from 0.5 and up to 4 hours interval. The dosage form is intended for once daily administration.

Abstract: An enteric coated pharmaceutical extended release dosage form of a H+, K+-ATPase inhibitor giving an extended plasma concentration profile of a H+, K+-ATPase inhibitor. The extended plasma profile is obtained by a pharmaceutical composition which comprises a core material of a hydrophilic or hydrophobic matrix, and the H+, K+-ATPase inhibitor and optionally pharmaceutically acceptable excipients. The dosage form may be administered once daily.

Abstract: A non-toxic oil-in-water or bicontinous microemulsion used as a pharmaceutically acceptable vehicle for administration of one or more active compounds having a low solubility in water as well as a process for the preparation and the use thereof.

Abstract: The present invention is directed to systems and methods for protecting a solar cell. The solar cell includes first solar cell portion. The first solar cell portion includes at least one junction and at least one solar cell contact on a backside of the first solar cell portion. At least one bypass diode portion is epitaxially grown on the first solar cell portion. The bypass diode has at least one contact. An interconnect couples the solar cell contact to the diode contact.

Abstract: The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+, K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.

Abstract: A process for transferring a decorative sublimation dye design formed on a transfer sheet to a continuous laminate by applying a sheet of cellulose web material impregnated with a thermosetting resin to a surface of a backer sheet to form a pre-laminate. A release sheet is applied to the exposed surface of the sheet of cellulose web material. The transfer sheet bearing the decorative sublimation dye design is applied to the exposed surface of the release sheet. Heat and pressure are applied to the pre-laminate layered with the release and transfer sheets, causing the cellulose web material to seep into the pores of the backer sheet to form a thermofused continuous laminate, and causing the design on the transfer sheet penetrates the thermofused continuous laminate through a sublimation process. The release and transfer sheets are then separated from the thermofused continuous laminate showing the transferred design.

Abstract: Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)methylphosphinic acid; ii) (S)-(3-amino-2-hydroxypropyl)methylphosphinic acid; iii) (R)-(3-amino-2-hydroxypropyl)methylphosphinic acid; iv) (3-amino-2-hydroxypropyl)difluoromethylphosphinic acid; and v) (3-amino-2-oxopropyl)methylphosphinic acid, having affinity to one or more GABAB receptors, their pharmaceutically acceptable salts, solvates and stereoisomers, as well as a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.

Abstract: A method of preparing drug particles of a substance which are susceptible to degradation by the use of a fluid gas technique.

Abstract: A mixing apparatus for preparing from a plurality of materials, preferably powders, in particular components of a pharmaceutical composition, a mixture having a required homogeneity, comprising a non-rotating mixing vessel (7); at least one feeding mechanism for feeding said materials into said vessel (7); a stirring means (31) inside said vessel (7) for preparing said mixture; and at least one measuring device (23) for monitoring in-line at one or more locations in said vessel (7) the homogeneity of the mixture being prepared therein, wherein said at least one measuring device (23) comprises a unit for directing input radiation into said vessel (7), and at least one detector unit (45) for detecting output radiation formed by interaction of said input radiation with said materials in said vessel (7).

Abstract: The integration of a programmable logic controller (PLC) and a motion control (NC) into a universal motion control (UMC) is realized by a tailored and nonetheless essentially user-configurable run-level model for processing of software tasks. This run-level model consists of types of different user levels and system levels with different priorities. In particular, one of the run levels (FA) can be configured very effectively according to user requirements. Thus, this kind of universal motion control (UMC) can be optimized by software to the particular requirements of the control task and the technical process.

Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.

Abstract: A primary package containing a low molecular weight peptide-based thrombin inhibitors which package is sealed with a rubber stopper or plunger containing bromobutyl rubber.